Skip to main content

Table 5 Chemotherapy outcome prediction using prognostic signatures

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Response prediction (n = sample size) BRmet50 PMID18271932Sig33 pCR RCB
pCR/RD(n = 993)*     
Mean PPV(SD) 88(6) 88(5) NA NA
Mean NPV(SD) 35(4) 35(6) NA NA
RCB(n = 417)**     
Mean PPV(SD) 85(1) 86(3) NA NA
Mean NPV(SD) 42(1) 41(0.3) NA NA
DRFS(n = 508)**     
Mean PPV(SD) 32(0.3) 31(2) 26(0.4) 49(2)
Mean NPV(SD) 88(6) 87(4) 92(0.8) 83(4)
  1. *Five data sets with neoadjuvant chemotherapy records include GSE25055 (anthracycline-taxane ), GSE25065 (anthracycline-taxane ), GDS4057(5-fluorouracil, doxorubicin, and cyclophosphamide), GSE32646 (5-fluorouracil-epirubicin, and cyclophosphamide), GSE41998 (doxorubicin and cyclophosphamide followed by ixabepilone or paclitaxel).
  2. **DRFS: Distant relapse free-survival, 508 samples from two data sets including GSE25055 and GSE25065.